Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years

The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher risk of nonrelapse mortality (NRM), including patients >40 years of age. We report results of a tim...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2015-05, Vol.29 (5), p.1041-1050
Main Authors: Cornelissen, J J, Versluis, J, Passweg, J R, van Putten, W L J, Manz, M G, Maertens, J, Beverloo, H B, Valk, P J M, van Marwijk Kooy, M, Wijermans, P W, Schaafsma, M R, Biemond, B J, Vekemans, M-C, Breems, D A, Verdonck, L F, Fey, M F, Jongen-Lavrencic, M, Janssen, J J W M, Huls, G, Kuball, J, Pabst, T, Graux, C, Schouten, H C, Gratwohl, A, Vellenga, E, Ossenkoppele, G, Löwenberg, B
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Adult
Antineoplastic Agents - chemistry
Autografts
Cancer
Chemotherapy
Conditioning
Disease-Free Survival
Female
Health aspects
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Leukemia
Leukemia, Myeloid, Acute - mortality
Leukemia, Myeloid, Acute - therapy
Male
Middle Aged
Multivariate Analysis
Myeloid leukemia
Proportional Hazards Models
Remission
Remission (Medicine)
Remission Induction
Risk
Stem cell transplantation
Stem cells
Survival
Time dependence
Time Factors
Transplantation
Transplantation Conditioning - methods
Transplantation, Homologous
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher risk of nonrelapse mortality (NRM), including patients >40 years of age. We report results of a time-dependent multivariable analysis of allogenic hematopoietic stem cell transplantation (alloHSCT) (n=337) versus chemotherapy (n=271) or autologous HSCT (autoHSCT) (n=152) in 760 patients aged 40-60 years with AML in CR1. Patients receiving alloHSCT showed improved overall survival (OS) as compared with chemotherapy (respectively, 57±3% vs 40±3% at 5 years, P
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2014.332